Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 15/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 6/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18940252 | 0.74 | KAT2A (0.33) | MAOAMAPT | |
| SCHEMBL7401281 | 0.74 | SMN1; SMN2 (0.46) | MAOASMN1; SMN2MAOBKDM4EPOLB | |
| SCHEMBL18919585 | 0.70 | CYP1A2 (0.44) | POLBMAPT | |
| SCHEMBL18919582 | 0.70 | CYP1A2 (0.44) | POLBMAPT | |
| SCHEMBL8693083 | 0.69 | KDM4E (0.36) | KDM4EMAPT | |
| SCHEMBL9404385 | 0.69 | KDM4E (0.36) | KDM4EMAPT | |
| SCHEMBL9154006 | 0.65 | PSMD14 (0.36) | — | |
| SCHEMBL160885 | 0.65 | — | — | |
| SCHEMBL13925646 | 0.64 | MAOA (0.57) | MAOAMAOBKDM4EPOLBMAPT | |
| SCHEMBL17356820 | 0.63 | PTPN1 (0.38) | MAOASMN1; SMN2MAOBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-62250046-A | — | — | None | — | — | JP | disclosed |
| US-6861419-B2 | Substituted 1, 4-thiazepine and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2005-03-01 | — | — | US | disclosed |
| EP-1324993-A2 | SUBSTITUTED 1,4-THIAZEPINE AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2003-07-09 | — | — | EP | disclosed |
| US-20020010169-A1 | Substituted 1, 4-thiazepine and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2002-01-24 | — | — | US | disclosed |
| WO-2001079187-A2 | SUBSTITUTED 1,4-THIAZEPINE AND ANALOGS AND THEIR USE AS ACTIVATORS OF CASPASES | CYTOVIA, INC. (US) | 2001-10-25 | — | — | WO | disclosed |
| JP-S62250046-A | CHLORINE-CONTAINING RESIN COMPOSITION | SAKAI CHEM IND CO LTD | 1987-10-30 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010169-A1 | Substituted 1, 4-thiazepine and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP1, CASP14, CASP4 | MAOA 2591/4885SMN1; SMN2 3992/4885MAOB 3740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.